top of page

Talking siRNAs with the CEO of Silence Therapeutics

Craig Tooman describes Silence's two lead programs targeting Lp(a) and polycythemia vera, as well as how the company is trying to execute on a broader platform.



Comentários


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page